ATI RN
ATI Proctored Pharmacology 2023
1. When should Montelukast be taken?
- A. At least two hours before exercise
- B. Daily in the evening
- C. Two hours before exercise or daily in the evening
- D. None of the above
Correct answer: B
Rationale: Montelukast should be taken daily in the evening to effectively manage asthma symptoms. Taking it at the same time each day helps maintain a consistent level of the medication in the body, providing optimal control over asthma symptoms and inflammation. Choice A is incorrect because Montelukast should not be taken specifically before exercise, but rather daily. Choice C is incorrect because although taking Montelukast two hours before exercise is not necessary, taking it daily in the evening is essential for its effectiveness. Choice D is incorrect as Montelukast should be taken daily to manage asthma.
2. A client with chronic myeloid leukemia is receiving hydroxyurea. Which of the following findings should the nurse monitor?
- A. Hyperkalemia
- B. Hypertension
- C. Neutropenia
- D. Tinnitus
Correct answer: C
Rationale: The nurse should monitor the client for neutropenia when receiving hydroxyurea. Neutropenia is a common adverse effect caused by bone marrow suppression. It is essential to assess the client's white blood cell count regularly to detect neutropenia early and prevent complications such as infections.
3. When caring for a client prescribed Digoxin, which of the following laboratory values should the nurse monitor to assess for potential toxicity?
- A. Sodium
- B. Potassium
- C. Magnesium
- D. Calcium
Correct answer: B
Rationale: When a client is prescribed Digoxin, monitoring potassium levels is crucial as hypokalemia can increase the risk of Digoxin toxicity. Low potassium levels can potentiate the effects of Digoxin on the heart, leading to toxicity. Therefore, regular monitoring of potassium levels helps in preventing adverse effects and ensuring the safe use of Digoxin. Sodium, magnesium, and calcium levels are not directly associated with Digoxin toxicity; hence, they are not the primary focus for monitoring in this case.
4. A client is taking Amiodarone to treat Atrial Fibrillation. Which of the following findings is a manifestation of Amiodarone toxicity?
- A. Light yellow urine
- B. Report of tinnitus
- C. Productive cough
- D. Blue-gray skin discoloration
Correct answer: D
Rationale: Blue-gray skin discoloration is a common sign of Amiodarone toxicity, known as blue-gray discoloration, which can affect areas like the face, neck, or hands. It is important to monitor for this side effect, as it can be a visible indicator of potential toxicity. Choices A, B, and C are incorrect. Light yellow urine is not typically associated with Amiodarone toxicity. Tinnitus is not a common manifestation of Amiodarone toxicity. A productive cough is not a recognized symptom of Amiodarone toxicity.
5. A client is prescribed Omeprazole for managing heartburn. What information should the nurse include in the teaching?
- A. Take this medication at bedtime.
- B. This medication decreases the production of gastric acid.
- C. Take this medication 2 hours after eating.
- D. This medication can cause hyperkalemia.
Correct answer: B
Rationale: The correct answer is B. The nurse should educate the client that Omeprazole works by reducing the production of gastric acid through inhibiting the enzyme responsible for its production. This action helps in managing heartburn and related symptoms effectively. Choice A is incorrect because Omeprazole is usually taken before eating. Choice C is incorrect as Omeprazole is typically taken before a meal. Choice D is unrelated to Omeprazole, as it is not associated with causing hyperkalemia.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access